Skip to content

RNTX RNTX Change in Accrued Liabilities

Change in Accrued Liabilities at other companies

Gilead Sciences logo
Gilead SciencesGILD
-$702M-188%
CTO
Citius Oncology, Inc.CTOR
$19.54M+684%
Gyre Therapeutics, Inc. logo
Gyre Therapeutics, Inc.GYRE
$683K-84.6%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$28.35M-1,019%
LQD
Liquidia CorporationLQDA
$14.53M+402%
4D Molecular Therapeutics logo
4D Molecular TherapeuticsFDMT
-$4.12M-78.3%

Other financials

Income statement

See full
Revenue-
Operating income-$5.2M+6.8%
Net income-$5.8M-6.1%
EPS (diluted)-$0.19+24.0%

Balance sheet

See full
Cash & equivalents$4.4M-40.2%
Total debt$48.0K0.0%
Total equity$6.9M-63.0%
Total assets$26.3M-54.4%

Cash flow

See full
Operating cash flow-$3.4M+44.6%
CapEx-
Free cash flow-$6.3M

Valuation

See full
Market cap$88.96M+164%

Returns & leverage

See full
Return on equity-123.3%+86.1pp
Debt / equity0.0×
Current ratio0.4×-1.0×

Where this comes from

Reported directly by RNTX in its filing.

Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities.

The official record: RNTX’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about RNTX's change in accrued liabilities.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is RNTX's change in accrued liabilities?
RNTX (RNTX) reported change in accrued liabilities of $247K in Q1 2026.
How has RNTX's change in accrued liabilities changed year-over-year?
RNTX's change in accrued liabilities increased by 2570.0% year-over-year, from -$10K to $247K.
What does change in accrued liabilities mean?
Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.